Literature DB >> 20005684

Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database.

M C Serna1, I Cruz, J Real, E Gascó, L Galván.   

Abstract

BACKGROUND: Many patients discontinue antidepressant therapy long before the six-month minimum duration recommended for the treatment of major depression and many other diagnoses.
PURPOSE: To estimate the duration of antidepressant treatment and to analyse the following factors in relation to treatment adherence: age, sex, polypharmacy and type of drug.
METHODS: Retrospective cohort followed up for five years (2003-2007) based on prescription database. SELECTION CRITERIA: Users who had received at least one antidepressant prescription in 2003 and who had not received antidepressants during the previous 12 months. VARIABLES STUDIED: Age, sex, drug, polypharmacy, period of treatment, packs dispensed. Adequate adherence was defined as dispensation of medication during at least 80% of the treatment period, and compliance was defined as good when, in addition, the treatment lasted more than four months.
RESULTS: Of the 7525 patients selected, 56% abandoned medication during the first four months. Men were more likely to give up medication before time than women. Good compliance was recorded in 22% of patients and was twice as frequent in patients with high levels of polypharmacy than in those with low levels (31% vs. 15.3%). Patients receiving maprotiline, venlafaxine, mirtazapine, citalopram, clomipramine and fluoxetine presented the highest percentages of good compliance.
CONCLUSIONS: Only one out of five patients complied with treatment for over four months. Treatment periods were shorter in men. In chronic processes, patients receiving polypharmacy presented the best compliance. (c) 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20005684     DOI: 10.1016/j.eurpsy.2009.07.012

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  34 in total

1.  Launching the 'war on mental illness'.

Authors:  J Licinio; M-L Wong
Journal:  Mol Psychiatry       Date:  2014-01       Impact factor: 15.992

2.  Antidepressant adherence: are patients taking their medications?

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2012-05

Review 3.  Translating biomarkers to clinical practice.

Authors:  R H Perlis
Journal:  Mol Psychiatry       Date:  2011-06-28       Impact factor: 15.992

4.  Predictors of Pharmacy-Based Measurement and Self-Report of Antidepressant Adherence: Are Individuals Overestimating Adherence?

Authors:  Amanda Leggett; Dara Ganoczy; Kara Zivin; Marcia Valenstein
Journal:  Psychiatr Serv       Date:  2016-02-14       Impact factor: 3.084

5.  Duration and compliance with antidepressant treatment in immigrant and native-born populations in Spain: a four year follow-up descriptive study.

Authors:  Inés Cruz; Catalina Serna; Montserrat Rué; Jordi Real; Jorge Soler-Gonzalez; Leonardo Galván
Journal:  BMC Public Health       Date:  2012-05-11       Impact factor: 3.295

6.  Factors associated with duration of new antidepressant treatment: analysis of a large primary care database.

Authors:  Christopher Burton; Niall Anderson; Katie Wilde; Colin R Simpson
Journal:  Br J Gen Pract       Date:  2012-02       Impact factor: 5.386

7.  Drug Overdose in a Retrospective Cohort with Non-Cancer Pain Treated with Opioids, Antidepressants, and/or Sedative-Hypnotics: Interactions with Mental Health Disorders.

Authors:  Barbara J Turner; Yuanyuan Liang
Journal:  J Gen Intern Med       Date:  2015-02-04       Impact factor: 5.128

8.  Seizures during antidepressant treatment in psychiatric inpatients--results from the transnational pharmacovigilance project "Arzneimittelsicherheit in der Psychiatrie" (AMSP) 1993-2008.

Authors:  M Köster; R Grohmann; R R Engel; M A Nitsche; E Rüther; D Degner
Journal:  Psychopharmacology (Berl)       Date:  2013-09-26       Impact factor: 4.530

9.  Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study.

Authors:  Jose A Franco-Chaves; Camilo F Mateus; David A Luckenbaugh; Pedro E Martinez; Alan G Mallinger; Carlos A Zarate
Journal:  J Affect Disord       Date:  2013-03-18       Impact factor: 4.839

10.  Physicochemical Characterization and Pharmacokinetics of Agomelatine-Loaded PLGA Microspheres for Intramuscular Injection.

Authors:  Hongjuan Zhang; Chenguang Pu; Qiao Wang; Xinyi Tan; Jingxin Gou; Haibing He; Yu Zhang; Tian Yin; Yanjiao Wang; Xing Tang
Journal:  Pharm Res       Date:  2018-11-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.